Topline results from the Chinese portion of the trial for the antibody-drug conjugate (ADC) TIVDAK support the company’s ...
Over the coming months, it is anticipated Pluvicto will be available for eligible patients at most of Ontario’s Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback